Download Head and Neck Cancer Drugs in the Pipeline

28
HemOnc today | APRIL 10, 2016 | Healio.com/HemOnc
Head and Neck Cancer Drugs in the Pipeline
HemOnc Today presents this guide to drugs in phase 2 or phase 3 development for head and neck cancer. Clinicians can use this chart as a quick reference to learn about the status
of those drugs that may be clinically significant to their practice.
Generic name (Brand name, Manufacturer) Indication(s)
Development status
ACP-196 (Acerta Pharma)
head and neck squamous cell carcinoma (combination therapy for advanced
disease)
phase 2
ADXS 11-001 (Advaxis)
oropharyngeal cancer (vaccination prior to robotic surgery for HPV-positive
disease)
phase 2
afatinib (Gilotrif, Boehringer Ingelheim)
head and neck squamous cell carcinoma
phase 3
AMG 319 (Amgen)
head and neck squamous cell carcinoma (HPV-negative disease)
phase 2
AZD5069 (AstraZeneca)
head and neck squamous cell carcinoma (combination therapy for relapsed,
metastatic disease)
phase 2
AZD9150 (AstraZeneca)
head and neck squamous cell carcinoma (combination therapy for relapsed,
metastatic disease)
phase 2
bevacizumab (Avastin, Genentech)
head and neck cancer (combined with chemotherapy for recurrent or metastatic disease)
phase 3
BIND-014 (BIND Therapeutics)
head and neck squamous cell carcinoma
phase 2
CetuGEX (Glycotope Group)
head and neck cancer
phase 2
durvalumab (AstraZeneca/MedImmune)
head and neck squamous cell carcinoma (monotherapy for second-line
treatment for PD-L1–positive disease; combination therapy for first-line and
second-line treatment; combination therapy for second-line treatment of
PD-L1–negative disease)
phase 3
E10A (Guangzhou Double Bioproducts)
head and neck squamous cell carcinoma
phase 3
GC4419 (Galera Therapeutics)
radiation-induced oral mucositis in patients with head and neck cancer
phase 2
GL-0817 (Gliknik)
squamous cell cancer of the oral cavity
phase 2
IMMU-132 (Immunomedics)
head and neck squamous cell carcinoma
phase 2
INC280 (Novartis)
head and neck squamous cell carcinoma (combination therapy for c-MET–
positive disease)
phase 2
INO-3112 (Inovio Pharmaceuticals)
head and neck cancer (HPV-associated disease)
phase 2
interleukin-12 gene therapy (ImmunoPulse, OncoSec Medical)
head and neck cancer
phase 2
IRX-2 (IRX Therapeutics)
squamous cell carcinoma of the oral cavity (newly diagnosed stage III or stage
IVA disease)
phase 2
leukocyte interleukin injection (Multikine, CEL-SCI Corporation)
squamous cell carcinoma of the oral cavity or soft palate
phase 3
MEDI4736 (MedImmune)
head and neck squamous cell carcinoma (combination therapy for relapsed,
metastatic disease)
phase 2
monalizumab (IPH2201, Innate Pharma)
head and neck squamous cell carcinoma (recurrent or metastatic disease)
phase 2
motolimod (VentiRx Pharmaceuticals)
head and neck cancer
phase 2
nivolumab (Opdivo, Bristol-Myers Squibb)
head and neck squamous cell carcinoma (recurrent or metastatic platinumrefractory disease)
phase 3
palbociclib (Ibrance, Pfizer)
head and neck cancer (combination therapy)
phase 2
patritumab (Daiichi Sankyo)
head and neck squamous cell carcinoma (combination therapy)
phase 2
pelareorep (Reolysin, Oncolytics Biotech)
head and neck squamous cell carcinoma (combination therapy for platinumrefractory recurrent or metastatic disease)
phase 3
pembrolizumab (Keytruda, Merck)
head and neck squamous cell carcinoma (locoregional inoperable recurrence
or second primary disease; surgically resectable disease)
phase 2
head and neck cancer
phase 3
PLX3397 (Plexxikon)
head and neck squamous cell carcinoma (combination therapy)
phase 2
SCB01A (SynCore Biotechnology)
head and neck cancer
phase 2
selinexor (Karyopharm Therapeutics)
head and neck squamous cell carcinoma (relapsed/refractory disease), salivary gland cancer
phase 2
TH-4000 (Threshold Pharmaceuticals)
head and neck squamous cell carcinoma (recurrent or metastatic disease)
phase 2
tremelimumab (AstraZeneca)
head and neck squamous cell carcinoma (combination therapy)
phase 2
veliparib (AbbVie)
head and neck cancer (combined with chemotherapy for stage IV disease)
phase 2
WNT974 (Novartis)
head and neck squamous cell carcinoma (metastatic disease)
phase 2
Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HemOnc Today. The
publisher or editors do not assume responsibility for any errors or omissions.